. Author manuscript; available in PMC: 2020 Jan 3.

Published in final edited form as: Prog Cardiovasc Dis. 2019 Jan 3;62(1):15–20. doi: 10.1016/j.pcad.2018.12.012

Table 1.

Summary of selected drugs with indication for obesity.

Medication	Mechanism of action	Efficacy
Orlistat	Gastrointestinal lipase inhibitor; prevents digestion of ~30% of ingested triacylglycerides.	60 mg, −2.5 kg (−1.5 to −3.5)^a, 120 mg, −3.4 kg (−3.2 to −3.6)^{a, 75}
Lorcaserin	Selective serotonin 2C (5-HT2C) receptor antagonist to reduce appetite.⁹²	10 mg, −3.6%^{b, 93}
Phentermine/Topiramate	Noradrenergic and GABA receptor activator; AMPK/KA receptor antagonist causing suppressed appetite.	7.5 mg/46 mg, −6.6%^{b, 94} 15 mg/92 mg, −8.6 to −9.3%^{b, 95}
Bupriopion/Naltrexone	Dopamine and norepinephrine reuptake inhibitor; opioid receptor antagonist	360 mg/32 mg, −6.1%^{b, 96}
Liraglutide	GLP-1 receptor agonist⁹⁷	3 mg, −8%^{b, 98}

Values indicate 1–7 weight change relative to placebo, Mean (95% CI), kg

Percentages indicate placebo-subtracted weight loss